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Abstract 
Background: Although oversedation has been associated with increased morbidity in ventilated critically ill patients, 
it is unclear whether prevention of oversedation improves mortality. We aimed to assess 90-day mortality in patients 
receiving a bundle of interventions to prevent oversedation as compared to usual care.
Methods: In this randomized multicentre trial, all adult patients requiring mechanical ventilation for more than 48 h 
were included. Two groups were compared: patients managed according to usual sedation practices (control), and 
patients receiving sedation according to an algorithm which provided a gradual multilevel response to pain, agitation, 
and ventilator dyssynchrony with no specific target to alter consciousness and no use of sedation scale and promoted 
the use of alternatives to continuous infusion of midazolam or propofol (intervention).
Results: Inclusions were stopped before reaching the planned enrolment. Between 2012 and 2014, 584 patients 
were included in the intervention group and 590 in the control group. Baseline characteristics were well balanced 
between groups. Although the use of midazolam and propofol was significantly lower in the intervention group, 
90-day mortality was not significantly lower (39.4 vs. 44.2% in the control group, p = 0.09). There were no significant 
differences in 1-year mortality between the two groups. The time to first spontaneous breathing trial and time to 
successful extubation were significantly shorter in the intervention group than in the control group. These last results 
should be interpreted with precaution regarding the several limitations of the trial including the early termination.
Conclusions: This underpowered study of severely ill patients was unable to show that a strategy to prevent overse-
dation could significantly reduce mortality.
Trial registration NCT01617265
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Background
Intravenous hypnotics, often combined with morphinics, 
are commonly used in mechanically ventilated patients 
in the intensive care unit (ICU) to control pain, agitation, 
and ensure synchrony with the ventilator [1]. However, 
the continuous infusion of midazolam or propofol often 
results in oversedation [2]. Factors involved in overseda-
tion are multiple, including drug pharmacokinetic and 
pharmacodynamic properties, inadequate objectives in 
terms of consciousness, and lack of frequent reassess-
ment of patient condition and hypnotic needs. Overse-
dation has been associated with prolonged mechanical 
ventilation and higher rates of nosocomial infections, 
ICU-acquired weakness, and delirium.
Strategies developed to avoid oversedation have been 
based either on (1) the use of continuous intravenous 
hypnotics combined with daily interruption of sedatives 
every 24 h [3], (2) the continuous titration of hypnotics 
according to predefined goals of comfort and conscious-
ness, with frequent patient assessments and prescription 
changes [4–7], or (3) the first-intention use of alternatives 
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to continuous intravenous midazolam or propofol [8–
10]. These strategies were associated with a reduction 
in mechanical ventilation duration. Few observational 
studies have assessed the impact of an oversedation pre-
vention strategy on mortality [10–13]. In a prospective 
observational study, Shehabi et al. reported that patients 
with deep sedation (indicated by at least one measure-
ment of Richmond Agitation Sedation Scale [RASS] − 3 
to − 5) during the first 48  h of mechanical ventilation 
were more likely to die in the ICU than patients with a 
lighter sedation (RASS − 2 to + 1), independently of 
age, comorbidities, and severity of acute illness [11]. To 
the best of our knowledge, this observation has not been 
confirmed in a randomized trial.
The main objective of the present randomized con-
trolled trial was to determine whether a strategy aiming 
to prevent oversedation could reduce 90-day mortality 
in critically ill patients requiring mechanical ventilation 
compared to usual care.
Methods
In accordance with French law, the study was approved 
by the institutional review board of Clermont-Ferrand, 
France, and by the Ethics Committee of the French 
Intensive Care Society (SRLF, Société de Réanimation de 
Langue Française). Informed consent or deferred consent 
was obtained from each patient or his/her legal surro-
gate. An independent data safety monitoring board had 
full access to the unblinded data.
Participants and settings
The study conducted by the SRLF Trial Group was 
planned as a parallel two-group individually randomized 
trial. Patients were eligible if they were aged 18 years or 
more, were receiving invasive mechanical ventilation for 
< 12  h, and had an expected invasive mechanical ven-
tilation duration > 48  h after randomization. Patients 
admitted after cardiac arrest, those with neuromuscular 
disease, tracheostomy, severe intracranial hypertension, 
status epilepticus, decision to withdraw care, or consid-
ered moribund were not included.
Oversedation prevention (OSP)
The OSP strategy was centred on the identification 
of patients’ level of agitation, ventilator asynchrony, 
and pain, on a 4-level scale, with gradual on-demand 
responses, frequent reassessments, and promotion of 
alternatives to continuous around-the-clock intravenous 
hypnotics infusion (Fig. 1). The alternatives to continuous 
infusion of midazolam or propofol in the intervention 
group were other benzodiazepines, antipsychotic agents, 
zolpidem, and hydroxyzine.
There was no aim to alter consciousness, and there-
fore, no sedation scale was used. However, conscious-
ness alteration could result from treatment of existing 
agitation, existing ventilator dyssynchrony, or existing or 
anticipated pain. During two national training and edu-
cation meetings, the OSP strategy was explained to inves-
tigators (usually an ICU doctor and nurse), who in turn 
implemented the OSP strategy in their own centre. OSP 
strategy posters were used at the bedside.
Usual care
Patients in the control group were treated according to 
the routine sedation practices used in each participat-
ing centre, reported in an pre-study survey of sedation 
practices in France [14]. In both intervention and control 
groups, the use of dexmedetomidine was not permitted. 
In both groups, pain was measured according to the cur-
rent practice in each participating centre. Weaning was 
conducted according to the French ICU Society guide-
lines [15].
Outcomes
The primary study endpoint was 90-day mortality after 
randomization. Secondary endpoints were day-28, hos-
pital and 1-year mortality, time from randomization to 
first spontaneous breathing trial, time to successful extu-
bation (defined as absence of invasive mechanical venti-
lation for 48 consecutive hours). Other outcome criteria 
are reported in Additional file 1: Appendix 1.
Randomization, allocation concealment, and blinding
Using a secure, computer-generated, interactive, web-
response system available at each study centre, patients 
were randomly assigned in a 1:1 ratio to study groups. 
Randomization was stratified by centre using permuta-
tion blocks of variable sizes. Sequences were generated 
by a biostatistician not involved in patient recruitment. 
Investigators had no access to the randomization list and 
were not aware of the size of the randomization blocks. 
Given the very nature of the assessed intervention, blind-
ing of the physicians and nurses was not feasible [16–18]. 
However, the primary outcome (death at day 90) is an 
objective one, which counterbalances this lack of blind-
ing [19].
Sample size
We assumed a mortality rate of 22% in the control group 
at day 90. To show a 5% absolute reduction in 90-day 
mortality in the OSP group, with a two-sided type I error 
of 5% and a power of 90%, the planned enrolment was 
2720 patients.
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Statistical analysis
Statistical analyses were conducted in the intention-
to-treat population. Data were described using counts 
and percentages or means and standard deviations (or 
median and interquartile range). Death proportions were 
compared using the Chi-square test, and mechanical 
ventilation-free days were compared using the Wilcoxon 
test. Time-dependent events were analysed using com-
peting risk models taking into account death and extuba-
tion. Description of the occurrence of these events was 
made using cumulative incidence curves. Cumulative 
incidence curves were compared between the two groups 
with the Fine and Gray test; hazard ratios (HRs) and their 
95% confidence intervals (95% CIs) were estimated by the 
competing risk models [20]. For the two patients (one 
in the OSP group and one in the control group) lost to 
follow-up for the primary outcome (90-day mortality), 
imputation of missing data (alive status) was performed. 
A two-tailed p value < 0.05 was considered statistically 
significant. Statistical analyses were performed using SAS 
version 9.4 (SAS Institute Inc) and R version 3.2.2 [21].
Fig. 1 Oversedation prevention (OSP) strategy was centred on patients’ level of agitation, ventilator dyssynchrony, and pain, assessed on a 4-level 
scale, with gradual on-demand responses, frequent reassessments, and promotion of alternatives to continuous around-the-clock infusion of 
intravenous hypnotics. These alternatives included frequent (every 6 h) intravenous hypnotic interruptions, intravenous boluses of hypnotics 
without continuous intravenous infusion, and the use of non-hypnotic drugs, including neuroleptics, hydroxyzine, and anxiolytic benzodiazepines. 
The choice of the non-hypnotic drugs and their route of administration (intravenous boluses or nasogastric tube) were left to the preference 
of the attending physician. There was no restriction for the use of morphinics and non-morphinic analgesics. Patient at Level 0, who showed 
no discomfort, received no treatment, or continuation of a successful level-1 therapeutic response (a). Patient at Level 1, with only moderate 
discomfort, pain, or anticipated procedural pain (b), received any form of analgesics as deemed necessary by the attending physician and/or 
non-hypnotic drugs as well as verbal reassurance and, if appropriate, changing of ventilator settings (c). Patients at Level 2, with severe agitation 
or ventilator dyssynchrony first received repeated intravenous boluses of either propofol or midazolam according to physician preferences, and, 
if discomfort persisted, 6-h continuous intravenous infusion of midazolam or propofol. This treatment was also applied in case of Level 1 therapy 
failure (which was maintained or stopped according to physician preference (d). Patients at Level 3, with ARDS and a  PaO2/FiO2 ratio < 150 mmHg, 
were treated with a continuous intravenous infusion of midazolam or propofol, with neuromuscular blocking agents administered according to 
physician preference. This treatment was also applied in the case of Level 2 therapy failure
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Results
Baseline characteristics
Forty-six ICUs were involved in the study. Of those, 18 
(39.1%) were university-affiliated, 15 (32.6%) were medi-
cal ICUs, and 31 (67.4%) medical surgical ICUs. Between 
July 2012 and July 2014, 1179 patients were included and 
randomized. The nurse/patient ratio was 2.5. The trial 
was stopped because of a decreasing average per centre 
recruitment rate, despite considerable help and encour-
agement. Five patients withdrew their consent and were 
therefore excluded from analysis, as requested by French 
law. Two patients (one in each group) were lost for the 
90-day follow-up and were arbitrarily considered alive 
(Fig. 2), leaving 584 patients in the OSP group and 590 in 
the control group available for the main analysis.
Table  1 shows the patients’ baseline characteristics, 
which were similar between the two groups. In the OSP 
and control groups, mean age (standard deviation) was 
66 (13) and 67 (14), mean simplified acute physiology 
score II (SAPS II) was 53.6 (17.8) and 54.4 (18.6), and 
54.5 and 53.0% of the patients were receiving norepi-
nephrine at randomization, respectively. Of note, chronic 
psychotropic medication use did not differ between the 
two groups, as shown in Table 1. At randomization, more 
than 65% of the patients were comatose (deep sedation or 
unarousable), as shown in Table 1. Sedation levels at ran-
domization are reported in Additional file 1: Appendix 2.
Outcomes
At day-90, 230 patients (39.4%) had died in the OSP 
group and 261 (44.2%) in the control group, p = 0.09. Of 
note those mortality rates were far higher than the ini-
tial sample size calculation of the trial. There were also 
no significant differences in day-28 (Table 2), in-hospital 
(Fig.  3), and 1-year mortality between the two groups 
(Table  2). Cumulative dosages of intravenous propofol 
and midazolam were significantly lower in the OPS group 
(Table  2). Cumulative dosage of intravenous sufentanil 
was significantly lower in the OPS group, whereas there 
was no significant difference in cumulative dosages of 
other morphinics between the two groups (Table 2).
First spontaneous breathing trial occurred significantly 
earlier in the OSP group than in the control group (HR 
1.18 [1.03–1.36], p = 0.015 (Additional file 1: Appendix 3, 
Figure). Similarly, successful extubation occurred signifi-
cantly earlier in the OSP group than in the control group 
(HR 1.15 [1.02–1.31], p = 0.03 (Additional file 1: Appen-
dix 3, Figure).
There was no significant difference in the other second-
ary outcomes, i.e. time to first sitting in a chair, time to 
first standing by the bed, presence of proximal muscle 
weakness, delirium, length of stay in the ICU (Table  2). 
Self-extubation was significantly more frequent in the 
OSP group than in the control group (70 vs. 48 events, 
HR 1.50 [1.04; 2.16], p = 0.03). Percentage of patients 
awake on a daily assessment between day 1 and day 7 are 
presented in the Additional file 1: Appendix 4.
Discussion
In this multicentre randomized study, we were unable 
to show that a gradual multilevel bundle strategy to pre-
vent oversedation could significantly reduce mortality of 
severely ill ICU patients requiring mechanical ventila-
tion. There were no significant differences between the 
two groups in in-hospital and 1-year mortality. However, 
oversedation prevention resulted in significantly less 
use of intravenous midazolam and propofol, and signifi-
cantly earlier weaning initiation and extubation. Last, the 
numerous limitations including early termination of the 
trial weaken the result interpretation.
We chose an OSP strategy centred on the identifica-
tion of patients’ level of agitation, ventilator asynchrony, 
and pain, on a 4-level scale, with gradual on-demand 
responses, frequent reassessments, and promotion of 
alternatives to continuous around-the-clock intravenous 
hypnotics (midazolam or propofol) infusion. Interest-
ingly, in the OSP algorithm, interventions were titrated 
only on patients’ needs to control pain, agitation, and 
ventilator asynchrony (except in the level 3), with no 
attempt to alter consciousness, even slightly, as a specific 
goal. Accordingly, the OSP strategy did not include the 
use of any sedation scale. Cumulative dosages of propo-
fol and midazolam were significantly lower in the OPS 
group. We did not use dexmedetomidine as an alterna-
tive to continuous intravenous hypnotics because at the 
time of study design, the very recent commercialization 
of dexmedetomidine in France precluded homogeneous 
and optimal use among the participating centres [22–25].
Our study was unable to show that the OSP strategy 
reduced mortality compared to standard care in critically 
ill patients. Furthermore, mortality was high in the study 
population. More than 40% of the patients had died at 
1179 randomized paents 
592 allocated to the control group
590 included in main analysis
587 allocated to the OSP group
584 included in main analysis
2 withdrew 
consent
3 withdrew 
consent
1 lost to 
follow-upa
1 lost to 
follow-upa
Fig. 2 Flowchart. aPatients lost to follow-up: imputation of missing 
data (alive vital status) was performed. OSP, oversedation prevention
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Table 1 Demographic and baseline characteristics at randomization
Control (n = 590) Oversedation 
prevention 
(n = 584)
Age (years), mean (SD) 67 (14) 66 (13)
Female gender, n (%) 200 (33.9) 202 (34.6)
BMI (kilograms divided by height in metres squared), mean (SD) 26.7 (6.6) 27.4 (7.1)
Chronic alcohol use, n (%) 115 (19.5) 126 (21.6)
Chronic psychotropic medication use, n (%) 177 (30.0) 166 (28.4)
 Benzodiazepine and related medications 110 (18.6) 109 (18.7)
 Neuroleptics 22 (3.7) 33 (5.7)
 Antidepressants 72 (12.2) 70 (12.0)
 Opioid medication 42 (7.1) 35 (6.0)
Tobacco use, n (%) 156 (26.5) 169 (28.9)
Liver cirrhosis with ascites or oesophageal varices, n (%) 34 (5.8) 37 (6.3)
Chronic renal replacement therapy, n (%) 9 (1.5) 10 (1.7)
Chronic respiratory insufficiency with home oxygen therapy, n (%) 42 (7.1) 51 (8.7)
NYHA class IV chronic heart failure, n (%) 16 (2.7) 23 (3.9)
Barthel score before admission, median (Q1–Q3) 100 (100–100) 100 (95–100)
Knauss chronic health status before admission, n (%)
 Normal health status 155 (26.3) 152 (26.0)
 Moderate activity limitation 285 (48.3) 267 (45.7)
 Severe activity limitation due to chronic disease 139 (23.6) 157 (26.9)
 Bedridden patient 11 (1.9) 8 (1.4)
MacCabe class before admission, n (%)
 No fatal disease 363 (61.5) 348 (59.6)
 Ultimately fatal disease 181 (30.7) 197 (33.7)
 Rapidly fatal disease 46 (7.8) 39 (6.7)
At home without assistance before current hospital admission, n (%) 373 (63.2) 367 (62.8)
ICU admission SAPS II score (first 24 h), mean (SD) 54.4 (18.6) 53.6 (17.8)
ICU admission SOFA score (first 24 h), median (Q1–Q3) 9 (7–12) 9 (7–12)
Medical admission, n (%) 520 (88.1) 530 (90.8)
Norepinephrine at randomization, n (%) 312 (53.0) 318 (54.5)
Midazolam at randomization (n1 = 493, n2 = 496), n (%) 412 (83.6) 421 (84.9)
Propofol at randomization (n1 = 493, n2 = 496), n (%) 74 (15.0) 69 (13.9)
Severe sepsis, n (%) 50 (8.5) 57 (9.8)
Septic shock, n (%) 339 (57.5) 323 (55.3)
ARDS, n (%) 186 (31.5) 187 (32.1)
ICU primary diagnosis
 Pulmonary infection, n (%) 246 (41.7) 239 (40.9)
 Abdominal infection, n (%) 49 (8.3) 54 (9.3)
 Other Infection, n (%) 41 (6.9) 57 (9.8)
 Cardiac failure or cardiogenic pulmonary oedema, n (%) 56 (9.5) 53 (9.1)
 COPD exacerbation or acute asthma, n (%) 51 (8.6) 51 (8.7)
 Acute pancreatitis, n (%) 9 (1.5) 13 (2.2)
 Drug intoxication, n (%) 12 (2.0) 9 (1.5)
 Metabolic disorder, n (%) 18 (3.1) 7 (1.2)
 Trauma, n (%) 7 (1.2) 7 (1.2)
 Acute stroke, n (%) 5 (0.8) 2 (0.3)
 Miscellaneous, n (%) 96 (16.3) 92 (15.8)
Sedation level on the RASS scale at  randomizationa
 Very agitated, n (%) 1 (0.4) 3 (1.1)
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3 months and almost 60% at 1 year. These mortality rates 
were much higher than anticipated at study design and 
higher than those reported in previous studies on light 
sedation strategies [1–13]. This high mortality very likely 
reflects the severity of the acute conditions at ICU admis-
sion, as suggested by a SAPS II score higher than com-
monly reported in trials on sedation [5, 8, 10, 25, 26]. Old 
age and the low rate of post-operative admissions both 
could have contributed to the high SAPS II. Similarly, the 
percentage of patients on vasoactive drugs at randomiza-
tion was high.
The severity of the acute conditions of our study 
population compared to previous studies suggests the 
inclusion of patients in real-life conditions. Demonstra-
tion of the positive impact of an intervention, such as a 
strategy to prevent oversedation, might be difficult in 
patients with particularly severe admission conditions 
and requires a larger sample of patients. In our study, less 
than half of the planned included patients were finally 
enrolled which undoubtedly makes the trial underpow-
ered. Furthermore, the planned inclusion number was 
based on a mortality rate of 22% in the control group. 
There is such a high difference between the a priori pos-
tulated mortality rate in the control group, and the a 
posteriori observed one (which is much closer to 50%) 
that even in case we would have been able to recruit the 
planned 2720 patients, the real power of the trial would 
have been much lower than the 90% nominal power.
Despite the severity of the conditions of the study 
patients, and the above limitations, the OSP strategy 
resulted in significantly shorter mechanical ventilation 
duration. Similar findings have been observed in previ-
ous randomized studies on light sedation in less severely 
ill ICU populations. This finding is important, as physi-
cians may be reluctant to adopt a light sedation strategy 
among the most severely ill patients. Indeed, as agitation 
and device removal may be perceived as particularly dan-
gerous in this population, physicians may favour continu-
ous intravenous sedation. The present trial did not show 
that oversedation prevention was associated with lower 
mortality, but it showed that it was associated with sec-
ondary benefits of faster weaning and extubation.
One explanation for shorter mechanical ventila-
tion duration is provided in our study by a significantly 
shorter time to first spontaneous breathing trial. An ade-
quate consciousness level is among the prerequisite crite-
ria for physicians to initiate the weaning process leading 
to extubation, along with other criteria including absence 
of high-grade fever, low oxygen, positive expiratory end-
pressure, and vasoactive drug needs [27]. A light sedation 
strategy might promote preservation of consciousness or 
early return to consciousness when other weaning crite-
ria are met [28].
Study limitations The numerous limitations includ-
ing the early termination and associated lack of power 
weaken the results.
We did not design a weaning protocol in the control 
group; patients were treated according to usual practice 
in the participating ICUs. Unfortunately, we do not have 
any data showing that the French ICU weaning guide-
lines were applied similarly in both groups. Physicians 
in the participating study centres might have uncon-
sciously changed their practice over the study period, 
with a progressive implementation of some aspects of 
the OSP strategy in control patients, further reducing the 
difference in sedation practices between the two groups. 
Insufficient compliance with the relatively novel multi-
level gradual intervention might also have reduced the 
difference in sedation practices between the two groups. 
A cluster randomization at the ICU level would have 
SD, standard deviation; BMI, body mass index; NYHA, New York Heart Association; Q1–Q3, 1st and 3rd quartiles; SAPS, Simplified Acute Physiology Score, SOFA, 
Sequential Organ Failure Assessment; ICU, intensive care unit, COPD, chronic obstructive pulmonary disease; ARDS, acute respiratory distress syndrome
a Sedation was measured using the RASS scale in 268 patients in the control group and 267 patients in the oversedation prevention group. The exact level on the 
RASS scale was not available for 3 patients in the control group and 5 patients in the oversedation prevention group.
Table 1 (continued)
Control (n = 590) Oversedation 
prevention 
(n = 584)
 Agitated, n (%) 4 (1.5) 1 (0.4)
 Restless, n (%) 3 (1.1) 5 (1.9)
 Alert and calm, n (%) 12 (4.5) 12 (4.6)
 Drowsy, n (%) 12 (4.5) 12 (4.6)
 Light sedation, n (%) 21 (7.9) 15 (5.7)
 Moderate sedation, n (%) 30 (11.3) 23 (8.8)
 Deep sedation, n (%) 63 (23.8) 66 (25.2)
 Unarousable, n (%) 119 (44.9) 125 (47.7)
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limited those group contamination issues; however, the 
risk of a selection bias associated with such a design was 
deemed greater and led us to choose an individual rand-
omization scheme [29–32]. This point remains a strong 
limitation to interpret the secondary endpoints in this 
non-blinded study.
The gap between estimated 90-day mortality used for 
the sample size calculation and the higher mortality rates 
observed also represents an important limitation study 
further reducing the study power.
Another limitation is that we did not use a sedation 
scale to measure the effect of the OSP strategy on con-
sciousness. This option was deliberately selected to avoid 
that clinicians would try to titrate IV sedatives to reach 
the common target of slightly altered consciousness in 
the intervention group, in which no specific alteration 
of consciousness should be targeted. Unfortunately, the 
surrogate markers for consciousness level used in the 
study (amounts of sedatives used, single daily assessment 
Table 2 Outcomes
For comparison of time dependent events analyzed using competing risks models to take into account competing risks as death or extubation (e.g. ventilator 
associated pneumonia), no percentages are provided
For comparison of variables in post-randomization sub-group (e.g. ICU length of stay in survivors), no P values are provided
CI, confidence interval; Q1–Q3, 1st and 3rd quartiles; MV, mechanical ventilation; VAP, ventilator-associated pneumonia; NIV, non-invasive ventilation; ICU, intensive 
care unit; LOS, length of stay
a Variables compared using the chi-square test
b Variables compared using the Wilcoxon test
c Variables analyzed using competing risks models to take into account competing risks (as death, extubation, ICU discharge, …). For each of these outcomes, Gray 
test P value and hazard ratio (95% confidence interval) from competing risks models were presented
Control (n = 590) Oversedation 
prevention 
(n = 584)
P value Hazard ratio 
(95% confidence 
interval)
28-day mortality 198 (33.6) 177 (30.4) 0.24a
90-day mortality 261 (44.2) 230 (39.4) 0.09a
1-year mortality 296 (60.0) 267 (56.5) 0.26a
Mechanical ventilation-free days at day 28 (days), median (Q1–Q3) 14 (0–24) 16 (0-24) 0.36b
Ventilator-associated pneumonia, n 92 94 0.79c 1.04 (0.78; 1.38)
Mechanical ventilation ≥ 48 h, n (%) 425 (72.0) 418 (71.6) 0.86a
Non-invasive ventilation after extubation, n (%) 152 (25.8) 177 (30.3) 0.08a
Duration of non-invasive ventilation after extubation (days), median (Q1–
Q3)
2 (1–4) 3 (2–4) 0.05b
Tracheostomy, n 26 24 0.81c 0.93 (0.54; 1.62)
Delirium, n 232 230 0.99c 1.00 (0.84; 1.19)
Proximal weakness after awakening, n 193 208 0.26c 1.11 (0.92; 1.35)
Patients with intravenous midazolam, n (%) 464 (78.6) 419 (71.8) 0.01a
Cumulative dosage of midazolam (mg), median (Q1–Q3) 263 (120–660) 218 (72–696) 0.03b
Patients with intravenous propofol, n (%) 232 (39.3) 214 (36.6) 0.34a
Cumulative dosage of propofol (mg), median (Q1–Q3) 2785 (645–7140) 1443 (120–4800) < 0.001b
Patients with intravenous morphinics, n (%) 501 (84.9) 482 (82.5) 0.31a
Patients with IV sufentanil, n (%) 263 (44.6) 241 (41.3) 0.28a
Cumulative dosage of sufentanil (µg), median (Q1–Q3) 930 (472–2592) 870 (280-2160) 0.04b
Patients with IV fentanyl, n (%) 204 (34.6) 206 (35.3) 0.8a
Cumulative dosage of fentanyl (µg), median (Q1–Q3) 4985 (2400–15,445) 4656 (1340–16,200) 0.29b
Patients with IV morphine, n (%) 73 (12.4) 91 (15.6) 0.1a
Cumulative dosage of morphine (mg), median (Q1–Q3) 17.5 (7–55) 20 (6–43) 0.69b
Patients with IV remifentanil, n (%) 49 (8.3) 45 (7.7) 0.7a
Cumulative dosage of remifentanil (µg), median (Q1–Q3) 14,400 (6000–28,800) 7200 (3000-19,200) 0.05b
Self-extubation, n 48 70 0.03c 1.50 (1.04; 2.16)
Ventricular tachycardia or fibrillation, n 18 21 0.61c 1.18 (0.63; 2.11)
Acute coronary syndrome or myocardial infarction, n 7 8 0.77c 1.16 (0.42; 3.18)
Cardiac arrest, n 20 13 0.22c 0.65 (0.33; 1.31)
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of consciousness base on a yes/no single-item scale, MV 
duration, etc.) all have their own limitations.
The oversedation prevention resulted in significantly 
less use of intravenous midazolam and propofol. Meas-
uring doses of drug and showing a reduction in doses 
administered is not the same thing, but the increased 
rate of awake patients in the OSP group may imper-
fectly reflect the goal. Unfortunately, an explicit record-
ing of implementation of multiple components of the 
OSP protocol could not be carried out in this large trial.
Of note, the lack of details regarding the previ-
ous alcohol consumption and the grouping within the 
large psychotropic category of medications with vari-
ous mechanisms of action and side effects (benzodi-
azepines, neuroleptics, antidepressants, etc.) albeit 
pragmatic also represents a potential methodological 
limitation.
In summary, in this prospective randomized trial in 
severe critically ill patients requiring mechanical ven-
tilation with early termination and under powering, we 
were unable to show that oversedation prevention sig-
nificantly reduces mortality. However, it resulted in a 
significantly lower use of intravenous hypnotics, earlier 
time to spontaneous breathing trial, and reduced dura-
tion of mechanical ventilation. These last results should 
be interpreted with precaution regarding the several 
limitations of the trial including the early termination.
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